Go to JCI Insight
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Alerts
  • Advertising/recruitment
  • Subscribe
  • Contact
  • Current Issue
  • Past Issues
  • By specialty
    • Cardiology
    • Gastroenterology
    • Immunology
    • Metabolism
    • Nephrology
    • Neuroscience
    • Oncology
    • Pulmonology
    • Vascular biology
    • All...
  • Videos
    • Conversations with Giants in Medicine
    • Author's Takes
  • Reviews
    • View all reviews...
    • Mechanisms Underlying the Metabolic Syndrome (Oct 2019)
    • Reparative Immunology (Jul 2019)
    • Allergy (Apr 2019)
    • Biology of familial cancer predisposition syndromes (Feb 2019)
    • Mitochondrial dysfunction in disease (Aug 2018)
    • Lipid mediators of disease (Jul 2018)
    • Cellular senescence in human disease (Apr 2018)
    • View all review series...
  • Collections
    • Recently published
    • In-Press Preview
    • Commentaries
    • Concise Communication
    • Editorials
    • Viewpoint
    • Scientific Show Stoppers
    • Top read articles
  • Clinical Medicine
  • JCI This Month
    • Current issue
    • Past issues

  • About
  • Editors
  • Consulting Editors
  • For authors
  • Current issue
  • Past issues
  • By specialty
  • Subscribe
  • Alerts
  • Advertise
  • Contact
  • Conversations with Giants in Medicine
  • Author's Takes
  • Recently published
  • Brief Reports
  • Technical Advances
  • Commentaries
  • Editorials
  • Hindsight
  • Review series
  • Reviews
  • The Attending Physician
  • First Author Perspectives
  • Scientific Show Stoppers
  • Top read articles
  • Concise Communication
Impaired osteoblastic differentiation, reduced bone formation, and severe osteoporosis in noggin-overexpressing mice
Xue-Bin Wu, … , Mone Zaidi, Etsuko Abe
Xue-Bin Wu, … , Mone Zaidi, Etsuko Abe
Published September 15, 2003
Citation Information: J Clin Invest. 2003;112(6):924-934. https://doi.org/10.1172/JCI15543.
View: Text | PDF
Categories: Article Bone biology

Impaired osteoblastic differentiation, reduced bone formation, and severe osteoporosis in noggin-overexpressing mice

  • Text
  • PDF
Abstract

We describe the effects of the overexpression of noggin, a bone morphogenetic protein (BMP) inhibitor, on osteoblast differentiation and bone formation. Cells of the osteoblast and chondrocyte lineages, as well as bone marrow macrophages, showed intense β-gal histo- or cytostaining in adult noggin+/– mice that had a LacZ transgene inserted at the site of noggin deletion. Despite identical BMP levels, however, osteoblasts of 20-month-old C57BL/6J and 4-month-old senescence-accelerated mice (SAM-P6 mice) had noggin expression levels that were approximately fourfold higher than those of 4-month-old C57BL/6J and SAM-R1 (control) mice, respectively. U-33 preosteoblastic cells overexpressing the noggin gene showed defective maturation and, in parallel, a decreased expression of Runx-2, bone sialoprotein, osteocalcin, and RANK-L. Noggin did not inhibit the ligandless signaling and pro-differentiation action of the constitutively activated BMP receptor type 1A, ca-ALK-3. Transgenic mice overexpressing noggin in mature osteocalcin-positive osteoblasts showed dramatic decreases in bone mineral density and bone formation rates with histological evidence of decreased trabecular bone and CFU-osteoblast colonies at 4 and 8 months. Together, the results provide compelling evidence that noggin, expressed in mature osteoblasts, inhibits osteoblast differentiation and bone formation. Thus, the overproduction of noggin during biological aging may result in impaired osteoblast formation and function and hence, net bone loss.

Authors

Xue-Bin Wu, Yanan Li, Adina Schneider, Wanqin Yu, Gopalan Rajendren, Jameel Iqbal, Matsuo Yamamoto, Mohammad Alam, Lisa J. Brunet, Harry C. Blair, Mone Zaidi, Etsuko Abe

×

Figure 6

Options: View larger image (or click on image) Download as PowerPoint
Effects of BMP and ca-ALK-3 overexpression on osteoblast differentiation...
Effects of BMP and ca-ALK-3 overexpression on osteoblast differentiation. (a) Concentration-dependent stimulation of ALP activity in mature OB-6 osteoblasts by BMP-2 and BMP-4, expressed as absolute values. (b) Concentration-dependent inhibition of ALP activity by noggin or PEG-noggin in the presence of a fixed dose of BMP-2 or BMP-4 (100 ng/ml), expressed as a percentage of the control value. (c) Anti-HA–immunostained U-33 cells documenting constitutively active BMP type 1A receptor (ca-ALK-3) expression; the left panel (Vector) is a negative control. (d) Effect of increasing concentrations (0–100 ng/ml for 3 days) of PEG-noggin in vector or ca-ALK-3–overexpressing U-33 cells as assessed by ALP activity (given as mean ± SEM), expressed as absolute values. *P < 0.05, significantly different from untreated control (Vector) cells; #P < 0.05, significantly different from ca-ALK-3 at 0 concentration, by ANOVA.
Follow JCI:
Copyright © 2019 American Society for Clinical Investigation
ISSN: 0021-9738 (print), 1558-8238 (online)

Sign up for email alerts